Chronic obstructive pulmonary disease (COPD) is an important preventable and treatable chronic respiratory disease characterized by airflow limitation, which is a serious health risk to people. The development of pulmonary hypertension in the late stages of COPD is an important cardiovascular complication and leads to chronic pulmonary heart disease and right heart failure, suggesting a poor prognosis. COPD is the 5th leading cause of death in the world and the 4th leading cause of death in the United States, with 1.6 million COPD patients, representing 5% of the world population. The latest COPD epidemiological survey in China shows that the total prevalence of COPD in people over 40 years of age is 8.2%, including 12.4% in men, 5.1% in women, 8.8% in urban areas and 7.8% in rural areas. It is estimated that there are 40 million people suffering from this disease in China, and the number of people who die from COPD is more than 1 million every year, and the number of people with disabilities is 5-10 million. According to the specific situation of each patient, individualized treatment and standardized treatment are combined to form a systematic treatment plan, and in accordance with the Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2007 Revised Edition), patients with COPD are provided with standardized treatment during the stable phase and acute exacerbation phase of COPD; objectives: 1. Rapidly control the acute exacerbation phase; 2. Reduce symptoms and stop the progression of the disease; 4. Alleviate or stop the decline of lung function; 5. Improve mobility and improve quality of life; 6. Reduce mortality.